HIV post-exposure prophylaxis: Difference between revisions
No edit summary |
|||
| Line 6: | Line 6: | ||
*Common side-effects = constitutional, gastrointestinal | *Common side-effects = constitutional, gastrointestinal | ||
===National Clinician's Post-Exposure Prophylaxis Hotline=== | |||
*1-888-448-4911, call for expert advice | |||
==Diagnosis== | |||
===Exposure Transmission Risk=== | ===Exposure Transmission Risk=== | ||
{| style="width: 500px" border="1" cellpadding="1" cellspacing="1" | {| style="width: 500px" border="1" cellpadding="1" cellspacing="1" | ||
| Line 70: | Line 74: | ||
**Truvada (tenofovir 300 mg + emtricitabine 200 mg) 1 PO once daily | **Truvada (tenofovir 300 mg + emtricitabine 200 mg) 1 PO once daily | ||
*If known source patient with resistant HIV strain, consult HIV service for source-patient-specific PEP | *If known source patient with resistant HIV strain, consult HIV service for source-patient-specific PEP | ||
==See Also== | ==See Also== | ||
Revision as of 18:58, 30 January 2015
Background
- Also known as HIV Post-Exposure Prophylaxis (PEP)
- ~79% transmission reduction
- Initiate ASAP (goal = <2 hours after exposure)
- >36 hours: normally deferred, unless particularly high risk
- Common side-effects = constitutional, gastrointestinal
National Clinician's Post-Exposure Prophylaxis Hotline
- 1-888-448-4911, call for expert advice
Diagnosis
Exposure Transmission Risk
| Exposure^ |
Risk |
| Percutaneous | 0.3% |
| Mucocutaneous | 0.09% |
| Needle-sharing injection drug | 0.7% |
| Receptive anal intercourse | 0.5% |
| Receptive penile-vaginal intercourse | 0.1% |
| Insertive anal intercourse | 0.07% |
| Insertive penile-vaginal intercourse | 0.05% |
| Receptive oral (male) intercourse | 0.01% |
| Insertive oral (male) intercourse | 0.005% |
^assumes no condom use
High Risk Exposures
Source
- Symptomatic HIV/AIDS
- Acute seroconversion
- High viral load
Exposure
- Deep injuries
- Visible blood on device
- Injuries sustained placing a catheter in a vein/artery
Workup (Before Giving)
- CBC
- C7
- LFTs
- Pregnancy test
Management
- CDC no longer recommends that the severity of exposure be used to determine the number of drugs to be offered and a regimen containing 3 antiretroviral drugs is now recommended routinely for all occupational exposures.[1]
Negligible Risk
- NOT recommended
Substantial Risk
- CDC preferred regimen for 28 days:[2]
- Raltegravir (isentress) 400 mg PO twice daily, plus
- Truvada (tenofovir 300 mg + emtricitabine 200 mg) 1 PO once daily
- If known source patient with resistant HIV strain, consult HIV service for source-patient-specific PEP
See Also
Source
- ↑ Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. August 6, 2013. http://www.jstor.org/stable/10.1086/672271 DOI: 10.1086/672271
- ↑ Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. August 6, 2013. http://www.jstor.org/stable/10.1086/672271 DOI: 10.1086/672271